Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608349 | 0.85 | SCN9A (0.39) | SCN9AALDH1A1SMN1; SMN2KMT2AOPRM1 | |
| SCHEMBL2306983 | 0.81 | SCN9A (0.39) | SCN9AALDH1A1SMN1; SMN2KMT2AOPRM1 | |
| SCHEMBL2305064 | 0.81 | KMT2A (0.42) | SCN9AALDH1A1SMN1; SMN2KMT2AOPRM1 | |
| SCHEMBL2306564 | 0.80 | SCN9A (0.39) | SCN9AALDH1A1SMN1; SMN2KMT2AOPRM1 | |
| SCHEMBL2307705 | 0.80 | SCN9A (0.39) | SCN9AALDH1A1SMN1; SMN2KMT2AOPRM1 | |
| SCHEMBL2305769 | 0.80 | KMT2A (0.48) | ALDH1A1SMN1; SMN2KMT2AOPRM1OPRD1 | |
| SCHEMBL3328359 | 0.78 | SMN1; SMN2 (0.38) | SCN9AALDH1A1SMN1; SMN2KMT2AOPRM1 | |
| SCHEMBL2306628 | 0.78 | ALDH1A1 (0.37) | SCN9AALDH1A1SMN1; SMN2OPRM1OPRD1 | |
| SCHEMBL281494 | 0.77 | OPRM1 (0.41) | ALDH1A1SMN1; SMN2KMT2AOPRM1OPRD1 | |
| SCHEMBL2305324 | 0.77 | OPRM1 (0.39) | SCN9AALDH1A1SMN1; SMN2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| CN-101627039-A | Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain | XENON PHARMACEUTICALS INC | 2010-01-13 | — | — | CN | disclosed |
| EP-2076514-A1 | SPIRO (FURO Ý3, 2-C¨PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008046049-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | SCN3A, SCN1B, SCN2B | SCN9A 38/4885ALDH1A1 866/4885SMN1; SMN2 739/4885 |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | SCN3A, SCN1B, SCN2B | SCN9A 38/4885ALDH1A1 866/4885SMN1; SMN2 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.